Summary
8-OH-DPAT (2.5–10 mg/kg) and buspirone (10 mg/kg) but not 5,7DHT (200 Μg/mouse), pCPA (75 and 150 mg/kg, three times), ritanserin (0.1 and 0.2 mg/kg), LY 53857 (1.5 and 3 mg/kg), GR 38032 F (0.1–100 Μg/kg), TFMPP (5 and 20 mg/kg) and mCPP (2.5 and 5 mg/kg) antagonized the rise in body temperature that occurs to the last mice removed from their group housing, which was termed as stress-induced hyperthermia (SIH). Ro 15-1788, at a dose which blocked the effect of diazepam on SIH, did not reverse the anxiolytic effect of buspirione. Instead, when cerebral 5-HT content was reduced to 50% by 5,7-DHT-induced lesion, the effect of buspirone on SIH was decreased. TFMPP 5 mg/kg did not shorten significantly the onset of SIH as could have been expected by an anxiogenic drug, while the dose of 20 mg/kg did not modify the pattern of SIH at all. The lower dose of TFMPP evoked a hyperthermic and the higher a hypothermic response.
Similar content being viewed by others
Abbreviations
- TFMPP:
-
m-trifluoromethylphenylpiperazine
- mCPP:
-
m-chlorophenylpiperazine
- pCPA:
-
P-chlorophenylalanine
- 5,7 DHT:
-
5,7 dihydroxytryptamine
- 8-OH-DPAT:
-
8-hydroxy-2-(di-N-propylamino)tetralin
- 5-HT:
-
serotonin
References
Bonanno G, Maura G, Raiteri M (1986) Pharmacological characterization of releaseregulating serotonin autoreceptors in rat cerebellum. Eur J Pharmacol 126: 317–321
Borsini F (1985) Randomization program for Apple IIe computer. Brain Res Bull 15: 279–281
Borsini F, Lecci A, Volterra G, Meli A (1989) A model to measure anticipatory anxiety in mice? Psychopharmacology 98: 207–211
Brittain RT, Butler A, Coates IH, Fortune DH, Hagan R, Hill JM, Humber DC, Humprey PPA, Ireland SJ, Jack DJ, Jordan CC, Oxford A, Straughan DW, Tyers MB (1987) GR 38032 F, a novel selective 5-HT3 receptor antagonist. Br J Pharmacol 90: 87 P
Carli M, Samanin R (1988) Potential anxiolytic properties of 8-hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist. Psychopharmacology 94: 84–91
Carli M, Prontera C, Samanin R (1989a) Effect of 5HT1A agonists of stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolyticlike activity. Neuropharmacology 28: 471–476
Carli M, Prontera C, Samanin R (1989b) Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br J Pharmacol 96: 829–836
Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healty subjects. Psychopharmacology 92: 14–24
Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 8: 383–388
Cohen ML, Kurz KD, Mason NR, Fuller RW, Marzoni GP, Garbrecht WL (1985) Pharmacological activity of the isomers of LY 53857, potent and selective 5-HT 2 antagonist. J Pharmacol Exp Ther 235: 319–323
Conn PJ, Sanders-Bush E (1987) Releative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT 1c) receptors. J Pharmacol Exp Ther 242: 552–557
Costall B, Kelly ME, Naylor RJ, Onaivi ES (1988) Actions of buspirone in a putative model of anxiety in the mouse. J Pharm Pharmacol 40: 494–500
Critchley MAE, Handley SL (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93: 502–506
Critchley MAE, Njung' K, Handley SL (1988) Prevention of 8-OH-DPAT anxiogenic effects by ipsapirone and by 5-HT 1A antagonist Β-adrenoceptor antagonists. Br J Pharmacol 94: 389 P
Davis M, Cassella JV, Kehene JG (1988) Serotonin does not mediate anxiolytic effects of buspirone an fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. Phsychopharmacology 94: 14–20
Dourish CT, Hutson PH, Curzon G (1986) Putative anxiolytics 8-OH-DPAT, buspirone and TVXQ 7821 are agonist at 5-HT 1A autoreceptors in the raphe nuclei. Trends Pharmacol Sci 7: 212–214
Eison AS, Davis MA, Temple JR (1986a) Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80 [Suppl 13B]: 1–9
Eison AS, Eison MS, Stanley M, Riblet LA (1986) Serotoninergic mechanisms in the behavioural effects of buspirone e gepirone. Pharmacol Biochem Behav 24: 701–707
Engel G, Gothert M, Hoyer D, Schlicker E, Hillenbrandt K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT 1B binding sites. Naunyn-Schmiedebergs Arch Pharmacol 332: 1–7
Engel JA, Hjort S, Svensson K, Carlsson A, Liljequist S (1984) Anticonflict effect of the putative serotonin receptor agonist 8-hyroxypropylamino) tetralin (8-OH-DPAT). Eur J Pharmacol 105: 365–368
File SE, Hyde JRG (1977) The effects of p-chlorophenylalanine and ethanolamine-Osulphate in an animal test of anxiety. J Pharm Pharmacol 29: 735–738
File SE, Johnston AL, Pellow S (1987) Effects of compounds acting at CNS 5-hydroxytryptamine systems on anxiety in the rat. Br J Pharmacol 90: 265 P
File SE, Johnston AL (1989) Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in rats. Psychopharmacology 99: 248–251
Frances H (1988) Psychopharmacological profile of 1-(m-(trifluoromethyl)phenyl)piperazine (TFMPP). Pharmacol Biochem Behav 31: 37–41
Goldberg HL, Finnerty RJ (1979) The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 136: 1184–1187
Goodwin GM, De Souza RJ, Green AR (1985) The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT). Neuropharmacology 24: 1187–1197
Gudelsky GA, Koenig JI, Meltzer HY (1986) Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Neuropharmacology 25: 1307–1313
Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12: 12–15
Higgins GA, Bradbury AJ, Jones BJ, Oakley NR (1988) Behavioural and biochemical activation of 5-HT 1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology 27: 993–1001
Hoyer D, Middlemiss DN (1989) Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci 10: 130–132
Hutson PH, Donohoe TP, Curzon G (1987) Hypothermia induced by the putative 5-HT 1A agonist LY 165163 and 8-OH-DPAT is not prevented by 5-HT depletion. Eur J Pharmacol 143: 221–228
Hutson PH, Sarna GS, O'Connell MT, Curzon G (1988) Decrease of hippocampal 5-HT release following infusion of 8-OH-DPAT into the dorsal raphe. Br J Pharmacol 94: 387 P
Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR 38032 F a 5-HT3-receptor antagonist. Br J Pharmacol 93: 985–993
Kennett GA, Curzon G (1988) Evidence that mCPP may have behavioural effects mediated by central 5-HT 1C receptors. Br J Pharmacol 94: 137–147
Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT 1C receptor antagonists. Eur J Pharmacol 164: 445–454
Klodzinska A, Jaros T, Cojnacka-Wojcik E, Maj J (1989) Exploratory hypoactivity induced by m-trifluoromethylphenyliperazine (TFMPP) and m-chlorophenylpiperazine (mCPP). J Neural Transm (P-D Sect) 1: 207–218
Lecci A, Borsini F, Volterra G, Meli A (1990) Pharmacological validation of a novel model of anticipatory anxiety. Psychopharmacology (in press)
Maj J, Chojnacka-Wojcik E, Klodzinska A, Deren A, Moryl E (1988) Hypothermia induced by m-trifluoromethylphenylpiperazine or m-chlorophenylpiperazine: an effect mediated by 5-HT 1B receptors? J Neural Transm 73: 43–55
Mansbach RS, Geyer MA (1988) Blockade of potentiated startle responding in rats by 5- hydroxytryptamine1A receptor ligands. Eur J Pharmacol 156: 375–383
Mennini T, Caccia S, Garattini S (1987) Mechanism of action of anxiolytic drugs. Progr Drug Res 31: 315–345
Morinan A (1989) Effects of the 5-HT3 receptor antagonists, GR 38032 F and BRL 24924, on anxiety in socially isolated rats. Br J Pharmacol 97: 457 P
Pazos A, Hoyer D, Dietl MM, Palacios JM (1988) Autoradiography of serotonin receptors. In: Osborne NN, Hamon M (eds) Neuronal serotonin. John Wiley & Sons, London, pp 507–543
Pei Q, Zetterstrom T, Fillenz M (1989) Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus. Neuropharmacology 28: 1061–1066
Peroutka SJ (1988) Functional correlates of central 5-HT binding sites. In: Osborne NN, Hamon M (eds) Neuronal serotonin. John Wiley & Sons, London, pp 423–447
Sertonin Club Receptor Nomenclature Committee (1990) Receptor nomenclature supplement. Trends Pharmacol Sci 11 [Suppl 16]
Sills MA, Barry B, Frazer W, Frazer A (1984) Determination of selective compounds for the 5-HT 1A and 5-HT 1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 231: 480–487
Sprouse JS, Aghajanian GK (1988) Responses of hippocampal pyramidal cells to putative serotonin 5-HT 1A and 5-HT 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27: 707–715
Taylor DP, Eison MS, Riblet LA, Vandermaelen CP (1985) Pharmacological and clinical effects of buspirone. Pharmacol Biochem Behav 23: 687–694
Traber J, Glaser T (1987) 5-HT 1A receptor-related anxiolytics. Trends Pharmacol Sci 8: 432–437
Tye NC, Evritt BJ, Iversen SD (1977) 5-Hydroxytryptamine and punishment. Nature 268: 741–743
Wise CD, Berger B, Stein L (1972) Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 177: 180–183
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lecci, A., Borsini, F., Mancinelli, A. et al. Effect of serotoninergic drugs on stress-induced hyperthermia (SIH) in mice. J. Neural Transmission 82, 219–230 (1990). https://doi.org/10.1007/BF01272765
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01272765